Healthcare Professional, Dive into the AI Revolution: Insights from insitro’s CEO Daphne Koller at PMWC 2024
We recently engaged in a discussion with Daphne Koller, CEO and founder of insitro and keynote speaker for the AI & Data Science Track at the PMWC 2024, and will explore opportunities and advancements that are emerging through the intersection of AI and data science.
Although the health of women has generally seen some improvements over the years, it is still insufficiently supported when it comes to clinical study representation in funding research and in drug development. Women’s health as a medical specialty should include a comprehensive slate of physical, mental, and social well-being and not just focus narrowly on the absence of disease.
The lack of specific guidelines on how to adjust medications based on genetic test results, and the difficulty in translating genetic test results into actionable prescribing decisions for affected drugs are the main reasons for the slow adoption of pharmacogenomic testing in the clinical setting.
New Monoclonal Antibody Drugs Slow Alzheimer’s Disease Progression – Leqembi & Donanemab (Healthcare Professional)
We are thrilled to share some groundbreaking developments in the field of precision medicine with you. Two promising new drug candidates, Leqembi and Donanemab, have shown great potential in slowing the progression of Alzheimer’s disease, marking a significant step forward in tackling this challenging condition.